Role of Bcl-3 in the development of follicular helper T cells and in the pathogenesis of rheumatoid arthritis

Arthritis and Rheumatology

Volumn 67, Issue 10, 2015, Pages 2651-2660

  Meguro, Kazuyuki ^a   Suzuki, Kotaro ^a   Hosokawa, Junichi ^a   Sanayama, Yoshie ^a   Tanaka, Shigeru ^a   Furuta, Shunsuke ^a   Ikeda, Kei ^a   Takatori, Hiroaki ^a   Suto, Akira ^a   Sakamoto, Akemi ^a   Ohara, Osamu ^b   Nakajima, Hiroshi ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KAZUSA DNA RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ACHAETE SCUTE HOMOLOG 2 PROTEIN; BETA ACTIN; CHEMOKINE RECEPTOR CXCR5; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 ALPHA; HEAT SHOCK PROTEIN 90 BETA; HERMES ANTIGEN; INDUCIBLE T CELL COSTIMULATOR; INTERLEUKIN 21; INTERLEUKIN 6; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN BCL 3; PROTEIN BCL 6; PROTEIN P50; RETINOID RELATED ORPHAN RECEPTOR GAMMA; STAT3 PROTEIN; TOCILIZUMAB; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTOME; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; INTERLEUKIN DERIVATIVE; ONCOPROTEIN; PROTO-ONCOGENE PROTEIN BCL-3; STAT3 PROTEIN, HUMAN;

ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; LYMPHOCYTE DIFFERENTIATION; MICROARRAY ANALYSIS; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; RHEUMATOID ARTHRITIS; RNA SEQUENCE; SIGNAL TRANSDUCTION; SIMPLIFIED DISEASE ACTIVITY INDEX; TFH CELL; TRANSCRIPTION REGULATION; TRANSCRIPTOMICS; TREATMENT RESPONSE; UPREGULATION; ANIMAL; C57BL MOUSE; CASE CONTROL STUDY; CELL CULTURE; DEFICIENCY; DNA MICROARRAY; DRUG EFFECTS; GENETICS; HELPER CELL; KNOCKOUT MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; CELLS, CULTURED; HUMANS; INTERLEUKIN-6; INTERLEUKINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTO-ONCOGENE PROTEINS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES, HELPER-INDUCER; TRANSCRIPTION FACTORS;

EID: 84958088068     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39266     Document Type: Article

References (45)

1. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010;376:1094-108.
2. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011;365:2205-19.
3. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet 2007;370: 1861-74.
4. Taylor PC, Feldmann M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol 2009;5:578-82.
5. Buch MH, Vital EM, Emery P. Abatacept in the treatment of rheumatoid arthritis. Arthritis Res Ther 2008;10 Suppl 1:S5.
6. Toh ML, Miossec P. The role of T cells in rheumatoid arthritis: new subsets and new targets. Curr Opin Rheumatol 2007;19:284-8.
7. Gizinski AM, Fox DA. T cell subsets and their role in the pathogenesis of rheumatic disease. Curr Opin Rheumatol 2014;26:204-10.
8. Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol 2011;29:621-63.
9. Crotty S. T follicular helper cell differentiation, function, and roles in disease. Immunity 2014;41:529-42.
10. He J, Tsai LM, Leong YA, Hu X, Ma CS, Chevalier N, et al. Circulating precursor CCR7loPD-1hiCXCR51CD41 T cells indicate Tfh cell activity and promote antibody responses upon antigen reexposure. Immunity 2013;39:770-81.
11. Wang J, Shan Y, Jiang Z, Feng J, Li C, Ma L, et al. High frequencies of activated B cells and T follicular helper cells are correlated with disease activity in patients with new-onset rheumatoid arthritis. Clin Exp Immunol 2013;174:212-20.
12. Ma J, Zhu C, Ma B, Tian J, Baidoo SE, Mao C, et al. Increased frequency of circulating follicular helper T cells in patients with rheumatoid arthritis. Clin Dev Immunol 2012;2012:827480.
13. Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray readerblinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007;66:1162-7.
14. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the Tocilizumab in Combination With Traditional Disease-Modifying Antirheumatic Drug Therapy study. Arthritis Rheum 2008;58:2968-80.
15. Saito Y, Kagami SI, Sanayama Y, Ikeda K, Suto A, Kashiwakuma D, et al. AT-rich-interactive domain-containing protein 5A functions as a negative regulator of retinoic acid receptor-related orphan nuclear receptor gt-induced Th17 cell differentiation. Arthritis Rheumatol 2014;66:1185-94.
16. Hayden MS, Ghosh S. Shared principles in NF-kB signaling. Cell 2008;132:344-62.
17. Hinz M, Arslan S, Scheidereit C. It takes two to tango: IkBs, the multifunctional partners of NF-kB. Immunol Rev 2012;246:59-76.
18. Sanayama Y, Ikeda K, Saito Y, Kagami SI, Yamagata M, Furuta S, et al. Prediction of therapeutic responses to tocilizumab in patients with rheumatoid arthritis: biomarkers identified by analysis of gene expression in peripheral blood mononuclear cells using genome-wide DNA microarray. Arthritis Rheumatol 2014; 66:1421-31.
19. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
20. Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005;23 Suppl 39:S100-8.
21. Suto A, Kashiwakuma D, Kagami S, Hirose K, Watanabe N, Yokote K, et al. Development and characterization of IL-21- producing CD41 T cells. J Exp Med 2008;205:1369-79.
22. Takahashi K, Hirose K, Kawashima S, Niwa Y, Wakashin H, Iwata A, et al. IL-22 attenuates IL-25 production by lung epithelial cells and inhibits antigen-induced eosinophilic airway inflammation. J Allergy Clin Immunol 2011;128:1067-76.
23. Arguni E, Arima M, Tsuruoka N, Sakamoto A, Hatano M, Tokuhisa T. JunD/AP-1 and STAT3 are the major enhancer molecules for high Bcl6 expression in germinal center B cells. Int Immunol 2006;18:1079-89.
24. Kashiwakuma D, Suto A, Hiramatsu Y, Ikeda K, Takatori H, Suzuki K, et al. B and T lymphocyte attenuator suppresses IL-21 production from follicular Th cells and subsequent humoral immune responses. J Immunol 2010;185:2730-6.
25. Suzuki K, Verma IM. Phosphorylation of SNAP-23 by IkB kinase 2 regulates mast cell degranulation. Cell 2008;134:485-95.
26. Wijaya E, Frith MC, Suzuki Y, Horton P. Recount: expectation maximization based error correction tool for next generation sequencing data. Genome Inform 2009;23:189-201.
27. Kishimoto T. Interleukin-6: from basic science to medicine—40 years in immunology. Annu Rev Immunol 2005;23:1-21.
28. Brocke-Heidrich K, Ge B, Cvijic H, Preifer G, Loffler D, Henze C, et al. BCL3 is induced by IL-6 via Stat3 binding to intronic enhancer HS4 and represses its own transcription. Oncogene 2006;22:7297-304.
29. Sweet RA, Lee SK, Vinuesa CG. Developing connections amongst key cytokines and dysregulated germinal centers in autoimmunity. Curr Opin Immunol 2012;24:658-64.
30. Hiramatsu Y, Suto A, Kashiwakuma D, Kanari H, Kagami S, Ikeda K, et al. c-Maf activates the promoter and enhancer of the IL-21 gene, and TGFb inhibits c-Maf-induced IL-21 production in CD41 T cells. J Leukoc Biol 2010;87:703-12.
31. Ohno H, Takimoto G, McKeithan TW. The candidate protooncogene bcl-3 is related to genes implicated in cell lineage determination and cell cycle control. Cell 1990;60:991-7.
32. Kelly KF, Daniel JM. POZ for effect: POZ-ZF transcription factors in cancer and development. Trends Cell Biol 2006;16:578-87.
33. Choi YS, Eto D, Yang JA, Lao C, Crotty S. STAT1 is required for IL-6-mediated Bcl6 induction for early follicular helper cell differentiation. J Immunol 2013;190:3049-53.
34. Nurieva RI, Chung Y, Martinez GJ, Yang XO, Tanaka S, Matskevitch TD, et al. Bcl6 mediates the development of T follicular helper cells. Science 2009;325:1001-5.
35. Lee SK, Silva DG, Martin JL, Pratama A, Hu X, Chang PP, et al. Interferon-g excess leads to pathogenic accumulation of follicular helper T cells and germinal centers. Immunity 2012;37: 880-92.
36. Gigoux M, Shang J, Pak Y, Xu M, Choe J, Mak TW, et al. Inducible costimulator promotes helper T-cell differentiation through phosphoinositide 3-kinase. Proc Natl Acad Sci U S A 2009;106:20371-6.
37. Hu H, Wu X, Jin W, Chang M, Cheng X, Sun SC. Noncanonical NF-kB regulates inducible costimulator (ICOS) ligand expression and T follicular helper cell development. Proc Natl Acad Sci U S A 2011;108:12827-32.
38. Vogelzang A, McGuire HM, Yu D, Sprent J, Mackay CR, King C. A fundamental role for interleukin-21 in the generation of T follicular helper cells. Immunity 2008;29:127-37.
39. Nurieva RI, Chung Y, Hwang D, Yang XO, Kang HS, Ma L, et al. Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. Immunity 2008;29:138-49.
40. Spolski R, Leonard WJ. Interleukin-21: a double-edged sword with therapeutic potential. Nat Rev Drug Discov 2014;13:379-95.
41. Liu SM, King C. IL-21-producing Th cells in immunity and autoimmunity. J Immunol 2013;191:3501-6.
42. Young DA, Hegen M, Ma HL, Whitters MJ, Albert LM, Lowe L, et al. Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis Rheum 2007;56:1152-63.
43. Liu R, Wu Q, Su D, Che N, Chen H, Geng L, et al. A regulatory effect of IL-21 on T follicular helper-like cell and B cell in rheumatoid arthritis. Arthritis Res Ther 2012;14:R255.
44. Robinson DS, O’Garra A. Further checkpoints in Th1 development. Immunity 2002;16:755-8.
45. Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol 2014;14:585-600.